BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 3, 2002
View Archived Issues
Elan's Abelcet, Sales Force Go To Enzon For $370M
Enzon Inc. signed an agreement with troubled Irish pharmaceutical company Elan Corp. plc to buy the North American and Japanese rights to Abelcet, Elan's drug for severe fungal infections, for $370 million in cash. (BioWorld Today)
Read More
Biosynexus Enters Antibacterial Deal With GSK Unit For $120M
Read More
Incurable Prion Diseases Open Crack To Resistance, Diagnosis, Drug Treatment, Gene Therapy
Read More
Panel's Advice Is Take The Money, Don't Count On An Open Window
Read More
Adherex, Oxiquant To Merge; Four Cancer Drugs In Basket
Read More
Deltagen Realignment Reduces Staff 30 Percent, Shuts Facility
Read More
Other News To Note
Read More